Loading company…
Okairos develops cellular immunotherapies and vaccine technologies for infectious diseases and cancer.
Founded in 2007 and based in Basel, Okairos developed immunotherapies and vaccines for infectious diseases and cancer. GlaxoSmithKline acquired the company in May 2013 for EUR 250 million.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in